Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+ CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon

Leukemia Research

Volumn 30, Issue 12, 2006, Pages 1577-1579

  Breccia, M ^a   Diverio, D ^a   Pane, F ^b   Nanni, M ^a   Russo, E ^a   Biondo, F ^a   Frustaci, A ^a   Gentilini, F ^a   Alimena, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CML; Complete molecular remission; Imatinib; Suspension

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; LONG TERM CARE; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; CYTOGENETIC ANALYSIS; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PIPERAZINES; PYRIMIDINES; RECTAL NEOPLASMS; RECURRENCE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 33749987744     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.03.011     Document Type: Article

References (9)

1. Kantarjian H.M., Cortes J.E., O'Brien S., Luthra R., Giles F., Verstovsek S., et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104 (2004) 1979-1988
2. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia-a Europe Against Cancer Program. Leukemia 17 (2003) 2318-2357
3. Mauro M.J., Druker B.J., and Maziarz R.T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28 Suppl. 1 (2004) S71-S73
4. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
5. Merante S., Orlandi E., Bernasconi P., Calabroni S., Boni M., and Lazzarino M. Outcome of four patients with chronic myeloid leucemia after imatinib mesylate discontinuation. Haematologica 90 (2005) 979-981
6. Rousselot P, Huguet F, Cayuela JM, Maarek O, Gluckman E, Reiffers J, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukaemia in complete remission for more than two years. ASH 2005; abstract no. 1101.
7. Angstreich G.R., Matsui W., Huff C.A., Vala M.S., Barber J., Hawkins A.L., et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 130 (2005) 373-381
8. Bonifazi F., de Vivo A., Rosti G., Guilhot F., Guilhot J., Trabacchi E., et al. Chronic myeloid leukaemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
9. Mahon F.X., Delbrel X., Cony-Makhoyul P., Faberes C., Boiron J.M., Barthe C., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20 (2002) 214-220